|Peer Comparison(?) I realize they are NOT apples to apples but all diagnostic testing disruptors specifically mentioned in DMTK's latest presentation|
Colorectal, Exact Sciences 'EXAS' @ $95.85 , MarketCap: ~$14,000,000,000
Lung, Guardant Health 'GH' @ $82.80 , MarketCap: ~$ 7,800,000,000
Prenatal, Natera 'NTRA' @ $36.51 , MarketCap: ~$ 2,900,000,000
Breast, Genomic Health 'GHDX' @ $63.44*, MarketCap: ~$ 2,400,000,000
Thyroid, Veracyte 'VCYT' @ $26.54 , MarketCap: ~$ 1,300,000,000
Heart, CareDx 'CDNA' @ $25.07 , MarketCap: ~$ 1,100,000,000
Skin, DermTech 'DMTK' @ $13.55 , MarketCap: ~$ 148,000,000
* GHDX quote prior to becoming part of EXAS
IMO, the future is bright for our still under the radar DMTK...
Please verify my dd..etc..etc....
| Reply to SunTzu772 - Msg #190 - 02/10/2020 11:39|
Re: ya 1.1M in one print..Fully active CMS coverage begins today.. Not sure...
Yes and of course with the 10-Q it'll be all about the guidance for the PLA for 2020-2021.